NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PDSB

PDS Biotechnology Corporation

Jun 30 • 04:00PM ET

1.33

Dollar change -0.08
Percentage change -5.67	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE AMGN MRK BNTX GSK BMY NKTR NVAX TGTX ONCY

| Held by: VTI VXF IWC BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.94	Insider Own	3.78%	Shs Outstand	45.45M	Perf Week	-13.64%
Market Cap	60.79M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	1.77%	Shs Float	43.98M	Perf Month	-5.00%
Enterprise Value	39.77M	PEG	-	EPS next Q	-0.23	Inst Own	18.00%	Short Float	4.52%	Perf Quarter	5.56%
Income	-35.50M	P/S	-	EPS this Y	13.59%	Inst Trans	3.99%	Short Ratio	4.01	Perf Half Y	-18.90%
Sales	0.00M	P/B	2.70	EPS next Y	3.00%	ROA	-61.18%	Short Interest	1.99M	Perf YTD	-18.40%
Book/sh	0.49	P/C	1.52	EPS next 5Y	5.96%	ROE	-119.22%	52W High	4.42 -69.91%	Perf Year	-56.25%
Cash/sh	0.87	P/FCF	-	EPS past 3/5Y	-16.00% 6.42%	ROIC	-123.41%	52W Low	0.85 56.38%	Perf 3Y	-64.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.10% 8.18%	Perf 5Y	-8.28%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	31.72%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	37.96	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.33	EPS Q/Q	31.22%	SMA20	-16.85%	Beta	1.23	Target Price	7.50
Payout	-	Debt/Eq	0.85	Sales Q/Q	-	SMA50	-7.42%	Rel Volume	1.06	Prev Close	1.41
Employees	24	LT Debt/Eq	0.29	Earnings	May 14 BMO	SMA200	-30.60%	Avg Volume	496.27K	Price	1.33
IPO	Oct 01, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.88% -	Trades		Volume	525,134	Change	-5.67%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-01-22	Initiated	B. Riley Securities	Buy	$10
Jun-28-21	Initiated	Cantor Fitzgerald	Overweight	$25
Nov-10-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6
May-27-20	Initiated	Alliance Global Partners	Buy	$4
Mar-09-20	Initiated	Noble Capital Markets	Outperform	$5.45
Oct-24-19	Initiated	Chardan Capital Markets	Buy	$10

Jun-09-25 08:00AM	PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune HPV for the Treatment of HPV16+ HNSCC (GlobeNewswire)
Jun-02-25 10:01AM	Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus (Zacks)
08:00AM	PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-25 10:55AM	PDS Biotechnology Corporation (PDSB)'s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial (Insider Monkey)
May-22-25 05:26PM	PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
08:00AM	Loading…
May-20-25 08:00AM	PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase (GlobeNewswire) +11.64%
May-15-25 03:09AM	PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:47AM	Q1 2025 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:38AM	PDS Biotechnology: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update (GlobeNewswire)
May-09-25 04:05PM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.50%
May-08-25 08:00AM	PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025 Annual Meeting (GlobeNewswire) +5.17%
May-07-25 08:00AM	PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results (GlobeNewswire)
Apr-23-25 10:16AM	PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +6.96%
Apr-16-25 08:00AM	PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025 Annual Meeting (GlobeNewswire) -6.31%
08:00AM	Loading…
Apr-08-25 08:00AM	PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Mar-28-25 03:01AM	PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
12:32AM	Q4 2024 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-27-25 10:35AM	PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update (GlobeNewswire)
Mar-25-25 08:00AM	PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference (GlobeNewswire)
Mar-23-25 08:52AM	PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-18-25 08:00AM	PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
07:22AM	FDA clears PDS Biotechnology's Versamune MUC1 combo for mCRC (Pharmaceutical Business Review)
Mar-13-25 08:00AM	PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer (GlobeNewswire) +5.88%
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-11-25 08:00AM	PDS Biotech Leadership to Participate in March Conferences (GlobeNewswire)
Mar-10-25 12:49PM	PDS Biotechnology commences trial for head and neck squamous cell carcinoma (Clinical Trials Arena)
Mar-07-25 08:45AM	PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer (GlobeNewswire) -8.21%
08:00AM	Loading…
Feb-27-25 08:00AM	PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -11.69%
Feb-26-25 08:00AM	PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology (GlobeNewswire) +22.22%
Feb-24-25 08:00AM	PDS Biotech Announces Circulating Tumor DNA Results for Versamune HPV in IMMUNOCERV Trial Published in Clinical Cancer Research (GlobeNewswire) -5.22%
Feb-20-25 08:00AM	PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 (GlobeNewswire)
Feb-05-25 08:00AM	PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Dec-06-24 08:00AM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.50%
Dec-03-24 08:00AM	PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET (GlobeNewswire)
Nov-20-24 09:35AM	Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround (Zacks)
Nov-15-24 02:08AM	PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -10.67%
Nov-14-24 08:07AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press Finance) -18.33%
08:00AM	PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time (GlobeNewswire)
Oct-22-24 12:00PM	PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
08:00AM	PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine (GlobeNewswire)
Oct-02-24 08:00AM	PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune HPV and Chemoradiation (GlobeNewswire) +12.60%
Sep-16-24 07:00AM	PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 (GlobeNewswire)
Sep-09-24 08:00AM	PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024 (GlobeNewswire)
Sep-03-24 08:00AM	PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.63%
Aug-13-24 08:09AM	PDS Biotechnology: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-08-24 08:00AM	PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting (GlobeNewswire)
Aug-07-24 08:00AM	PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 08:00AM	PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024 (GlobeNewswire)
Aug-01-24 07:45AM	PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) -9.27%
Jul-31-24 04:01PM	PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time (GlobeNewswire)
Jul-29-24 08:00AM	PDS Biotech to Participate at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-12-24 08:00AM	PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer (GlobeNewswire) +6.16%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-15-24 12:52PM	PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024 (InvestorPlace)
08:08AM	PDS Biotechnology: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 05:49AM	PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study (MT Newswires) -8.36%
May-09-24 05:46PM	PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer (GlobeNewswire)
08:00AM	PDS Biotech to Participate in Upcoming May 2024 Investor Conferences (GlobeNewswire)
May-07-24 08:00AM	PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024 (GlobeNewswire)
May-03-24 08:00AM	PDS Biotechnology Announces Details of Virtual KOL Event (GlobeNewswire)
May-02-24 08:00AM	PDS Biotech Appoints Stephan Toutain as Chief Operating Officer (GlobeNewswire)
Apr-23-24 08:00AM	PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) +7.02%
Mar-28-24 10:24AM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-27-24 11:33PM	Q4 2023 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents) -14.06%
11:52AM	PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023 (InvestorPlace)
08:51AM	PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update (GuruFocus.com)
07:30AM	PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results (GlobeNewswire)
Mar-13-24 10:55AM	The 3 Most Undervalued Biotech Stocks to Buy in March 2024 (InvestorPlace)
08:00AM	PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune (GlobeNewswire)
Jan-22-24 04:45PM	PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer (GlobeNewswire) +12.03%
Jan-16-24 08:00AM	PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire) -5.44%
Jan-02-24 12:00PM	All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy (Zacks)
Dec-04-23 04:50PM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-23 07:30AM	PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer (GlobeNewswire) -9.66%
Nov-15-23 01:03PM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ... (GuruFocus.com) +18.55%
07:42AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-23 08:00AM	PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Na ve Patients at 36 Months (GlobeNewswire) +5.36%
Nov-07-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 08:00AM	PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO (GlobeNewswire)
Oct-11-23 08:00AM	PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer (GlobeNewswire)
Oct-03-23 07:00AM	PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Na ve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA (pembrolizumab) (GlobeNewswire) -14.47%
Oct-02-23 08:00AM	PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) (GlobeNewswire) -6.93%
Sep-26-23 08:00AM	PDS Biotech to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-25-23 08:00AM	PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 (GlobeNewswire)
Sep-20-23 04:05PM	PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
08:00AM	PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies (GlobeNewswire)
Sep-13-23 08:00AM	PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:00AM	PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference (GlobeNewswire)
Aug-29-23 11:32AM	PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why (Zacks) -6.56%
Aug-16-23 08:00AM	PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting (GlobeNewswire) +5.95%

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Freitag Gregory Gene	Director	Feb 28 '25	Buy	1.66	15,060	25,000	61,213	Mar 03 04:45 PM
Glover Stephen C.	Director	Feb 28 '25	Buy	1.66	15,061	25,001	78,851	Mar 03 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PDSB

PDS Biotechnology Corporation

Upgrade your FINVIZ experience